Three Bills, One Biopsy: How Dermatopathology Quietly Leaks Revenue Through Patient Collections

The Read With a Sub-50% Patient Collection Rate

The 2026 Medicare Physician Fee Schedule pays roughly $70 globally for CPT 88305, the level-IV surgical pathology read that handles the overwhelming majority of skin biopsies. The fee splits roughly evenly between the technical component (TC, slide prep) and the professional component (PC, the dermatopathologist's interpretation). High volume. High margin. Clean to code. Clean to post.

And clean to bill. The patient-responsibility share is the line that doesn't collect.

Per HFMA, citing athenahealth data from a study of 1,850 hospitals and 250,000 physicians, the average patient collection rate sits at 47.6%, and just 6% of physician balances above $200 are collected. A path bill almost always lands in that >$200 bucket once the technical and professional components stack, and on HDHP patients before a deductible is met, it lands far above that. (Comparable industry data from Kodiak Solutions documented a parallel slide — 54.8% in 2021 down to 47.8% in 2022 and 2023, per TechTarget's summary.)

The HDHP Shift That Put Path Bills in the Danger Zone

The patient-responsibility share of provider revenue keeps growing while the willingness to pay it keeps falling. The KFF Employer Health Benefits Survey tracked HDHP-with-savings-option enrollment from 27% of covered workers in 2024 to 33% in 2025. Average single-coverage deductibles hit $1,787. The share of workers carrying a $2,000+ deductible has climbed five points in five years.

For a fully-met-deductible patient, a $185 path read is rounding error. For an HDHP patient at $1 of $3,000 spent, the path read is the bill. And it's the bill that arrives last — weeks after the patient has already paid the visit copay and largely forgotten about the encounter. The deductible-reset dynamic that compresses January collections in dermatology patient collections compounds here, because the path bill posts deeper into the deductible window than the visit charge that triggered it.

Three Bills, One Biopsy: The Structural Confusion

The path bill is structurally engineered to confuse the patient. The biopsy procedure itself — CPT 11102 (tangential) or a 113xx-series excisional code — posts on the date of service. The 88305 read is generated days later, on the dermatopathologist's signing cadence. If the practice doesn't have in-house dermpath, an outside lab bills the patient directly — often from a corporate entity the patient has never heard of, often four to six weeks after the visit.

From the patient's vantage point, one encounter becomes three statements:

• Bill #1: office visit and procedure (the visit copay, biopsy charge)
• Bill #2: technical component (slide prep), branded by the lab
• Bill #3: professional component (the read), often a separate statement, sometimes from a separate billing entity

By the time Bill #3 arrives, the patient has lost the thread. The connection between “the biopsy I had at the dermatologist” and “this $340 bill from a lab I don't recognize” is gone. The same dynamic shows up in the AR data as a charge-lag pattern we've documented before in path-specific revenue loss: 90+ day buckets fill quietly while the dashboard still looks healthy.

Why the No Surprises Act Doesn't Reach the Path Bench

The instinct is to assume the No Surprises Act fixed this. It didn't. The NSA's facility-based balance-billing protection only triggers in hospitals, ambulatory surgery centers, and emergency departments. An office-based skin biopsy doesn't meet that trigger. And the College of American Pathologists' 2022 letter to CMS named the structural reason no transparency framework will fully retrofit this setting:

Pathologists are not the initiator of the tissue or fluids submitted for diagnosis, and will know neither what will be submitted nor what will need to be done until the pathologist has reviewed the original specimen(s).

A dermatopathologist can't quote a price before they look at the slide because they don't know whether the final code is 88304, 88305, or 88307. The transparency machinery that defused anesthesia surprise bills was built for a setting derm path doesn't operate in. The disclosure burden lands on the convening provider — the practice — not on the lab.

The Good Faith Estimate rule is the real perimeter

Under 45 CFR §149.610, self-pay and uninsured patients have a Good Faith Estimate right at scheduling or within three business days of request. Civil monetary penalties run up to $10,000 per violation. The patient-provider dispute resolution threshold sits at $400 above the GFE. CMS has kept the co-provider GFE piece — estimates that bundle the outside lab's charges with the practice's — under enforcement discretion. The convening-provider rule on the practice's own services is live today. That distinction will not last forever, and the Compliance Team's read is that path-bill disclosure is the most likely area for that discretion to expire next.

In-House Dermatopathology: Amplifier or Fix?

Bringing dermpath in-house is often pitched as the solution to the patient-confusion problem. Done well, it is. Done without an updated financial policy and a result-delivery script, it amplifies the problem.

The volume math gets quoted often. Per Dermatology Times, roughly 4,000 specimens per year is the floor where slide-prep economics start to work; 8,000–10,000 slides per year produces a payback period near six months on the equipment investment. Dedicated lab space runs about 200 sq ft, and a histotech salary sits in the mid-to-high five figures depending on certification level (HT vs. HTL) and region. The equipment investment itself — cryostat, fume hood, slide stainer, microscope — runs from a sub-$25K basic setup at the volume floor up through six figures for a fully-automated lab at the 10,000-slide tier. If the volume is there, the unit economics are compelling.

But the patient now receives two clearly-practice-branded bills: the TC from the in-house lab and the PC from the in-house dermatopathologist. To the patient, the second statement looks like a duplicate of the first one, and the practice fields the dispute call instead of getting paid. Same revenue capture problem, different blame surface.

The Contrast That Defines the Leak

The practices that have figured this out aren't waiting for a regulator to mandate it. Tareen Dermatology's financial policy tells patients upfront that “you may receive a statement for your office visit and procedure before receiving a statement that includes any related pathology service charges,” that biopsy charges run “$180–$220 for each biopsy” with separate pathology charges of “$100–$600,” and that an HDHP patient who has not met a deductible “should plan on owing in the neighborhood of $280–$820 per biopsy.”

The same disclaimer paragraph, near-verbatim, now appears on the GFE pages of at least four other groups including Aesthetic Dermatology Associates, North Dallas Dermatology, Compassion Dermatology, and Forefront. The industry has implicitly admitted in its legal language that this is the surprise patients need to be warned about by name. Most practices have not yet matched that admission with a patient-facing communication script at the point of biopsy.

State law adds another disclosure layer

The federal GFE perimeter is not the only one. Several states have built more aggressive structures around clinical-lab and pathology billing:

• California: Anti-markup statutes at Cal. Bus. & Prof. Code §655.5 (clinical laboratory) and the more directly relevant §655.7 (anatomic pathology) bar marking up an outside lab's charge, require the lab's name and charge to appear separately on the first bill, and carry up to $10,000 in fines per violation.
• New York: Public Health Law §587 prohibits a long list of lab business practices — fee-splitting, kickbacks, percentage commissions, fake invoice forms — on top of the §586 requirement that the lab bill the recipient of services directly.
• Florida: The patient brokering statute at Fla. Stat. §456.054 defines kickbacks broadly enough that fair-market-value per-specimen TC arrangements can implicate it — the same concern OIG flagged in Advisory Opinion 23-06 (September 2023), which named dermatology specifically when warning that per-specimen TC payments can still implicate the Anti-Kickback Statute. The advisory opinion isn't statute, but it's the OIG telling derm where it's looking.

What the Compliance Team Recommends

Bottom Line

The practices figuring this out aren't doing it for compliance points. Patient-responsibility AR is the chokepoint for path revenue, and confusion is the chokepoint for patient payment. In a year when the conversion factor is still under pressure and HDHP enrollment keeps climbing, the practices that fix the path-bill experience first will collect more of the revenue they've already earned.